Mink Therapeutics Stock Performance
| INKT Stock | USD 0.70 0.05 6.67% |
The company secures a Beta (Market Risk) of 0.63, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Mink Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Mink Therapeutics is expected to be smaller as well. At this point, Mink Therapeutics has a negative expected return of -0.26%. Please make sure to verify Mink Therapeutics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Mink Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Mink Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's forward-looking signals remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
1 | Acquisition by Corvese Brian of 21802 shares of Mink Therapeutics at 0.82 subject to Rule 16b-3 | 09/03/2024 |
2 | MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 | 10/04/2024 |
3 | Disposition of 695750 shares by Jennifer Buell of Mink Therapeutics subject to Rule 16b-3 | 10/16/2024 |
4 | MiNKs iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024 | 11/07/2024 |
5 | MiNK Therapeutics stock target cut, rating held amid pipeline updates | 11/15/2024 |
6 | MiNK Therapeutics Receives Buy Rating from HC Wainwright | 11/18/2024 |
| Begin Period Cash Flow | 19.6 M |
Mink |
Mink Therapeutics Relative Risk vs. Return Landscape
If you would invest 84.00 in Mink Therapeutics on August 21, 2024 and sell it today you would lose (14.00) from holding Mink Therapeutics or give up 16.67% of portfolio value over 90 days. Mink Therapeutics is currently does not generate positive expected returns and assumes 2.3767% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Mink, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mink Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mink Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mink Therapeutics, and traders can use it to determine the average amount a Mink Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1099
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INKT |
Estimated Market Risk
| 2.38 actual daily | 21 79% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Mink Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mink Therapeutics by adding Mink Therapeutics to a well-diversified portfolio.
Mink Therapeutics Fundamentals Growth
Mink Stock prices reflect investors' perceptions of the future prospects and financial health of Mink Therapeutics, and Mink Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mink Stock performance.
| Return On Equity | -12.39 | ||||
| Return On Asset | -0.97 | ||||
| Current Valuation | 25.76 M | ||||
| Shares Outstanding | 39.54 M | ||||
| Price To Book | 10.05 X | ||||
| EBITDA | (22.25 M) | ||||
| Net Income | (22.46 M) | ||||
| Cash And Equivalents | 29.85 M | ||||
| Cash Per Share | 0.88 X | ||||
| Total Debt | 22.61 M | ||||
| Current Ratio | 1.74 X | ||||
| Book Value Per Share | (0.42) X | ||||
| Cash Flow From Operations | (15.76 M) | ||||
| Earnings Per Share | (0.48) X | ||||
| Market Capitalization | 29.81 M | ||||
| Total Asset | 4.55 M | ||||
| Retained Earnings | (133.4 M) | ||||
| Working Capital | (7.8 M) | ||||
About Mink Therapeutics Performance
Assessing Mink Therapeutics' fundamental ratios provides investors with valuable insights into Mink Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mink Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.93) | (5.18) | |
| Return On Capital Employed | 3.35 | 3.51 | |
| Return On Assets | (4.93) | (5.18) | |
| Return On Equity | 1.24 | 1.18 |
Things to note about Mink Therapeutics performance evaluation
Checking the ongoing alerts about Mink Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mink Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mink Therapeutics generated a negative expected return over the last 90 days | |
| Mink Therapeutics has some characteristics of a very speculative penny stock | |
| Mink Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.46 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mink Therapeutics currently holds about 29.85 M in cash with (15.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.88, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Mink Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 75.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: MiNK Therapeutics Receives Buy Rating from HC Wainwright |
- Analyzing Mink Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mink Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Mink Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mink Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mink Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mink Therapeutics' stock. These opinions can provide insight into Mink Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mink Stock Analysis
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.